Wu Tsai Neurosciences Institute


Showing 21-30 of 490 Results

  • Gill Bejerano

    Gill Bejerano

    Professor of Developmental Biology, of Computer Science, of Pediatrics (Genetics) and of Biomedical Data Science

    Current Research and Scholarly Interests1. Automating monogenic patient diagnosis.
    2. The genomic signatures of independent divergent and convergent trait evolution in mammals.
    3. The logic of human gene regulation.
    4. The reasons for sequence ultraconservation.
    5. Cryptogenomics to bridge medical silos.
    6. Cryptogenetics to debate social injustice.
    7. Managing patient risk using machine learning.
    8. Understanding the flow of money in the US healthcare system.

  • Sean Bendall

    Sean Bendall

    Assistant Professor (Research) of Pathology

    Current Research and Scholarly InterestsOur goal is to understand the mechanisms regulating the development of human systems. Drawing on both pluripotent stem cell biology, hematopoiesis, and immunology, combined with novel high-content single-cell analysis (CyTOF – Mass Cytometry) and imagining (MIBI-Multiplexed Ion Beam Imaging) we are creating templates of ‘normal’ human cellular behavior to both discover novel regulatory events and cell populations as well as understand dysfunctional processes such as cancer.

  • Jonathan Berger

    Jonathan Berger

    Denning Family Provostial Professor

    BioJonathan Berger is the Denning Family Provostial Professor in Music at Stanford University, where he teaches composition, music theory, and cognition at the Center for Computer Research in Music and Acoustics (CCRMA).
    Jonathan is a 2017 Guggenheim Fellow and a 2016 winner of the Rome Prize.
    He was the founding co-director of the Stanford Institute for Creativity and the Arts (SICA, now the Stanford Arts Institute) and founding director of Yale University’s Center for Studies in Music Technology
    Described as “gripping” by both the New York Times and the Chicago Tribune, “poignant”, “richly evocative” (San Francisco Chronicle), “taut, and hauntingly beautiful” (NY Times), Jonathan Berger’s recent works deal with both consciousness and conscience. The Kronos Quartet toured recent monodrama, My Lai internationally. Thrice commissioned by The National Endowment for the Arts, Berger’a recent commissions include The Mellon and Rockefeller Foundations, Chamber Music Society, Lincoln Center, and Chamber Music America. Upcoming commissions include an oratorio entitled The Ritual of Breath, and Leonardo, for baritone and chamber orchestra.
    In addition to composition, Berger is an active researcher with over 80 publications in a wide range of fields relating to music, science and technology and has held research grants from DARPA, the Wallenberg Foundation, The National Academy of Sciences, the Keck Foundation, and others.

  • Rebecca Bernert

    Rebecca Bernert

    Assistant Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)

    BioI am an Assistant Professor of Psychiatry and Behavioral Sciences and a licensed clinical psychologist in the Stanford University School of Medicine. I am a suicidologist, with subspecialty expertise in clinical trials, epidemiology, and suicide prevention best practices. I have joint specialty in behavioral sleep medicine and treatment development. I am founding Director of The Suicide Prevention Research Laboratory, and Co-Chair an initiative to establish a Stanford Center for Suicide Prevention. Our research program utilizes cognitive, biological (e.g., fMRI), and behavioral testing paradigms, with an emphasis on translational therapeutics across the lifespan. Our mission is to identify novel therapeutic targets for suicide prevention, including seminal work in establishing the subfield of sleep and suicide prevention. A special focus of our work is the development of rapid-action, low-risk interventions for the prevention of suicide. Our mission is to evaluate transdiagnostic risk factors and biomarkers underlying treatment response that may inform etiology, reduce stigma, and advance innovation. Advocating for its utility as a visible, yet non-stigmatizing warning sign of suicide—our earliest work delineated sleep as an evidence-based risk factor for suicidal behaviors. Funded by NIH and DOD, we subsequently conducted the first suicide prevention clinical trials, testing efficacy of a rapid-action (6 h) insomnia treatment for suicidal behaviors. These use a mechanisms focus to identify central disease processes (eg, underlying neural circuitry, behavioral factors) in the pathogenesis of risk for anti-suicidal response. An overarching aim is to harness new technologies to aid risk prediction, precision medicine, and intervention opportunity. We are also committed to improving national training practices and high risk monitoring of suicidal behaviors (e.g., national needs-assessment of medical training parameters; use of AI for suicide prevention; study of sleep as an ER target to enhance acute intervention).

    Regarding translation to policy, I have served as a content expert for nationally-directed health initiatives with NIH, VA, DOD, DARPA, SAMHSA, CDC, and The White House. I recently led development of the CA 2020 Statewide Strategy for Suicide Prevention, following invited testimony (CA State Assembly) and a commissioned Policy Brief on suicide prevention best practices. Additional advisory and advocacy work centers on how research guides public health policy and implementation. I am especially committed to initiatives that promise impact to suicide prevention on a broad scale, including universal strategies for lethal means restriction and real-time surveillance of suicidal behaviors. To this end, I have been honored to serve as a content expert to The White House Office of Science and Technology for initiatives focused on technology innovation and led advisory work promoting suicide deterrent systems for private organizations and public sites, such as the Golden Gate Bridge. I have consulted for technology companies, as well as private industry and healthcare partners. Last, inspired by maternity leaves coinciding with the above work, I have a separate research line examining organizational development, inclusive practices, and employee wellness. This addresses disparate impact of institutional and federal medical leave practices on recruitment and retention of women. Our program focuses on cost-effective policy for diversity training and reduced attrition of women in medicine, law, STEM and technology fields. As such, I am dedicated to spearheading development of a center for policy and inclusive practices, diversity, and equity education.

    To donate to our work or partner with us, please contact Stanford Medical Center Development at medicalgiving@stanford.edu to connect with us directly or to learn more about supporting our programs.

  • Edward Bertaccini

    Edward Bertaccini

    Professor of Anesthesiology, Perioperative and Pain Medicine

    Current Research and Scholarly Interestsmolecular modeling of anesthetic-protein interactions, molecular modeling of the ligand-gated ion channels

  • Carolyn Bertozzi

    Carolyn Bertozzi

    Baker Family Director of Stanford ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology

    BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.

    Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.

    Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.

    The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.

    Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly.

  • Sandip Biswal, MD

    Sandip Biswal, MD

    Associate Professor of Radiology (Musculoskeletal Imaging)
    On Partial Leave from 08/25/2021 To 05/31/2022

    Current Research and Scholarly InterestsThe management of individuals suffering from chronic pain is unfortunately limited by poor diagnostic tests and therapies. Our research group is interested in 'imaging pain' by using novel imaging techniques to study peripheral nociception and inflammation with the goal of accurately identifying the location of pain generators. We are developing new approaches with positron emission tomography (PET) and magnetic resonance imaging (MRI) (PET/MRI) and are currently in clinical trials.

  • Jose Humberto Blanchet Mancilla

    Jose Humberto Blanchet Mancilla

    Professor of Management Science and Engineering

    BioJose Blanchet holds a Ph.D. in Management Science and Engineering from Stanford University. Prior to joining MSandE he was a faculty member of Columbia and Harvard University. Jose is a recipient of the 2009 Best Publication Award given by the INFORMS Applied Probability Society and of the 2010 Erlang Prize. He also received a PECASE award given by NSF in 2010. He worked as an analyst in Protego Financial Advisors, a leading investment bank in Mexico. He has research interests in applied probability and Monte Carlo methods. He serves in the editorial board of Advances in Applied Probability, Journal of Applied Probability, Mathematics of Operations Research, QUESTA, Stochastic Models, and Stochastic Systems.

  • Helen M. Blau

    Helen M. Blau

    Donald E. and Delia B. Baxter Foundation Professor, Director, Baxter Laboratory for Stem Cell Biology and Professor, by courtesy, of Psychiatry and Behavioral Sciences
    On Partial Leave from 01/01/2021 To 12/31/2021

    Current Research and Scholarly InterestsProf. Helen Blau's research area is regenerative medicine with a focus on stem cells. Her research on nuclear reprogramming and demonstrating the plasticity of cell fate using cell fusion is well known and her laboratory has also pioneered the design of biomaterials to mimic the in vivo microenvironment and direct stem cell fate. Current findings are leading to more efficient iPS generation, cell based therapies by dedifferentiation a la newts, and discovery of novel molecules and therapies.